<DOC>
	<DOCNO>NCT00423644</DOCNO>
	<brief_summary>The study safety new organic arsenic compound treatment advance multiple myeloma</brief_summary>
	<brief_title>A Phase II Trial ZIO-101 Advanced Multiple Myeloma : Protocol SGL2001b</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects confirm diagnosis active multiple myeloma measurable protein criterion present evaluate response . Measurable disease define least one follow criterion within 28 day prior registration : 1 . Serum Mprotein level &gt; 0.5 gm/dl ( 10.0 g/L ) measure serum protein electrophoresis . 2 . Urinary Mprotein excretion &gt; 0.2 g/24 hour urine electrophoresis . 2 . Subjects must relapse resistant disease , define either relapse resistant &gt; 2 line prior therapy myeloma . A minimum 42 day must elapse since prior autologous allogeneic transplant ; 3 . Informed consent compliant ZIOPHARM policy approve Human Investigation Review Committee jurisdiction site ; 4 . ECOG performance score ≤ 1 ; 5 . No chemotherapy , bortezomib , lenalidomide , thalidomide , arsenic trioxide , radiation therapy immune therapy ≥ 3 w recover treatment associate toxicity prior registration ; 5a . Patients may receive equivalent 10 mg prednisone per day 2 week prior registration . 6 . Age ≥ 18 ; 7 . Granulocytes ≥ 1.0 x 109/L ; platelet ≥ 50 x 109/L ; 8 . Bilirubin ≤ 2.0 mg/dL ; AST ALT ≤ 2 x ULN ; 9 . Creatinine ≤ 3 X ULN . 10 . No investigational agent within 28 day study entry . 11 . Males agree use doublebarrier method birth control , ( Double barrier method define : condom either diaphragm/cervical cap IUD ) . Exclusion Criteria 1 . NYHA functional class ≥ 3 , myocardial infarction ≤ 6 mo uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation ; QTc ≥ 450msec ; AVblock ≥ grade2 LBBB ; 2 . Women childbearing potential . ( Nonchildbearing potential define : surgical sterilization 2 year postmenopausal ) 3 . Active infection require antibiotic ; 4 . Allergy ZIO101 excipients ; 5 . Baseline confusion dementia , define grade &gt; 2 CTCAE Version 3.0 ; 6 . Significant neurotoxicityneuropathology , define grade &gt; 2 neurotoxicity neuropathology per CTCAE Version 3.0 ; 7 . Prior seizure ≥ grade3 CTC v.3 criterion . 8 . Prior history neurological deficit ( e.g. , stroke , dementia , ischemia ) potential confound postdose neurological assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>arsenic</keyword>
	<keyword>cancer study</keyword>
	<keyword>fail treatment</keyword>
</DOC>